Open the map

DexComDXCM

Diabetes & metabolic disease · NASDAQ · USA

$84.41
Up 0.1% todayClose

Up 27.0% this year and +20.3% since June 26, ahead of the life science sector at +10.7%. DexCom supplies 1 mapped company.

Market cap
$31.8B
This year
+27.0%
1 year
+27.7%
P/E
31.8
P/S
6.4
P/B
12.1

Price vs the life science sector

since Jun 26DXCMLife science sector, equal weight
DexCom (DXCM) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. DXCM: +20.3% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%+30%Jun 26AugSepOct 8DXCM +20.3%Sector +10.7% DexCom (DXCM) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. DXCM: +20.3% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%+30%Jun 26AugSepOct 8DXCM+20.3%Sector+10.7%

Supply chain

1 customer
SUPPLIERS →→ CUSTOMERSNone mappedCVS Health (CVS)CVSCVS Health−0.2%DXCMDexCom

Customers 1

Open the full chain →

About DexCom

Continuous glucose monitoring for people with diabetes: the G-series sensors, and Stelo, which is sold over the counter.

Theme exposure

DiabetesGlucose monitoringMedtech exposureDigital health

Products

  • CGM sensors (G-series)
  • Stelo (OTC)
  • Diabetes software

Competitors

Risks

  • Price competition
  • Reimbursement changes

Same segment: Diabetes & metabolic disease

Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring. Segment 1 of 8 in the Medicine, pharma & life science value chain.

Eli LillyLLY−1.6%InsuletPODD+0.1%

Compare DXCM

Side by side with the largest companies in the same segment.

DXCM vs LLYDXCM vs PODD

See where DexCom sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →